You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Low Cost, Efficient Microchannel Plasma Ozone System for Point of Use Water Treatment

    SBC: EP Purification, Inc.            Topic: A

    A team at EP Purification has performed research for the development and commercialization of low-cost microchannel plasma reactor modules capable of efficiently producing ozone for water treatment and other environmental applications in a slim form factor and size. The conservation of water resources for human consumption is a growing national priority. Ozone is a unique purification agent as it ...

    SBIR Phase II 2014 Environmental Protection Agency
  2. Biofuel Production from Grease Trap Waste

    SBC: Environmental Fuel Research, LLC            Topic: F

    Environmental Fuel Research, LLC, proposes to commercialize a grease trap waste to biofuel process based on process research from Drexel University. Grease trap waste is dirty and low-value material produced by the food service industry that is high in lipids that can be converted to biodiesel. The quantity of grease trap waste in the United States could produce one-half billion gallons of biodies ...

    SBIR Phase I 2014 Environmental Protection Agency
  3. Web-Based Training in Alcohol SBIRT for Youth Aged 9-18

    SBC: Oregon Center For Applied Science, Inc            Topic: NIAAA

    DESCRIPTION (provided by applicant): Underage alcohol consumption is a public health concern with numerous negative sequelae, including adoption of other risky behaviors (smoking, other drug use, at-risk sexual behavior, drinking and driving), increased rates of depression or suicidal ideation, poor academic achievement, and behavioral problems (delinquency, violence, crime). Adolescents who drink ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Mobile Intervention to Enhance Physical Activity in the Chronically Ill

    SBC: Oregon Center For Applied Science, Inc            Topic: NIA

    PROJECT SUMMARY This project aims to fill the urgent need for a safe and engaging intervention that promotes physical activity in a population of patients with chronic diseases (e.g., diabetes, asthma, osteoarthritis, and chronic heart failure). Compelling evidence suggests that physical activity is an effective therapeutic intervention for numerous chronic diseases. However, in spite of the wide ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Microfluidic screening devices for health-span extending drugs

    SBC: NEMAMETRIX, INC            Topic: NIA

    Aging, the progressive degeneration of body and mind, is a universal problem marked by a decline in tissue organization and function, and an increase in the likelihood of death. Progress in understanding the cellular and molecular basis of aging is rapidlyaccelerating, following the discovery that several well-known model organisms age in many of the same ways as humans. In addition to their contr ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Local Lymph Node Assay with IL-18 Endpoints

    SBC: MB RESEARCH LABORATORIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The current industry standard for predicting contact dermal sensitization is the murine Local Lymph Node Assay (LLNA). A significant limitation of the LLNA is the frequency of false positives, as well as the occurrenceof false negatives. This limitation occurs as a result of the LLNA inability to always correctly distinguish between substances that are strongly ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Ubiquitin pathway inhibitors for treatment of asthma

    SBC: Progenra, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Asthma is a chronic disease with considerable morbidity and no cures. Symptomatic treatment is efficacious but produces significant adverse effects. Thus, improved, targeted therapies for asthma are needed. Asthma develops when T cells (CD4+) differentiate to effector T cells, which secrete cytokines that assist in the recruitment and proliferation of various i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite improvements in vaccine design, manufacture, and distribution, influenza A infection remains a significant public health concern. The February 2013 CDC Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness reported overall vaccine effectiveness of 56% and 67% against influenza A and B infections, respectively, with much reduced effect ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A New Generation of Botulinum Toxin Vaccines

    SBC: INVENTOX INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum toxin is one of the six categories of pathogens that have been designated as Category A Select Agents by the Centers for Disease Control. The toxin, which is generally acknowledged to be the most potent biological poison known, enters the body and acts on peripheral cholinergic nerve endings to cause paralysis of transmission. In seriously poisoned pa ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A Single Antiviral to Treat Multiple Opportunistic Infections

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Transplant patients are quite susceptible to opportunistic viral infection resulting from immune suppression necessary for maintenance of their graft. In the case of renal transplant, 17,604 patients in 2011, a new graft means being taken off dialysis, improving quality of life and saving U.S. healthcare nearly 1 B annually. Therefore it is essential that the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government